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Borrelia burgdorferi, the spirochete that causes Lyme disease, binds decorin, a collagen-associated extracel-
lular matrix proteoglycan found in the skin (the site of entry for the spirochete) and in many other tissues. Two
borrelial adhesins that recognize this proteoglycan, decorin binding proteins A and B (DbpA and DbpB,
respectively), have recently been identified. Infection of mice by low-dose B. burgdorferi challenge elicited
antibodies against DbpA and DbpB that were sustained at high levels, suggesting that these antigens are
expressed in vivo. Scanning immunoelectron microscopy showed that DbpA was surface accessible on intact
borreliae. Passive administration of DbpA antiserum protected mice from infection following challenge with
heterologous B. burgdorferi sensu stricto isolates, even when serum administration was delayed for up to 4 days
after challenge. DbpA is the first antigen target identified that is capable of mediating immune resolution of
early, localized B. burgdorferi infections. DbpA immunization also protected mice from B. burgdorferi challenge;
DbpB immunization was much less effective. DbpA antiserum inhibited in vitro growth of many B. burgdorferi
sensu lato isolates of diverse geographic, phylogenetic, and clinical origins. In combination, these findings
support a role for DbpA in the immunoprophylaxis of Lyme disease and suggest that DbpA vaccines have the
potential to eliminate early-stage B. burgdorferi infections.
Lyme disease (53), or Lyme borreliosis, is caused by a group
of related tick-borne spirochetes classified as Borrelia burgdor-
feri sensu lato (including B. burgdorferi sensu stricto, B. afzelii,
and B. garinii). Although much progress has been made in the
characterization of the organism, spirochetal factors responsi-
ble for infectivity, immune evasion, and disease pathogenesis
remain largely obscure. The most-studied B. burgdorferi mem-
brane protein is outer surface protein A (OspA), a lipoprotein
antigen expressed by borreliae in resting ticks and the most
abundant protein expressed in vitro by most B. burgdorferi
sensu lato isolates (2, 32). Experimental OspA vaccines have
demonstrated efficacy in several animal models (11, 19, 24, 33),
and OspA vaccines for human use are the subjects of current
clinical evaluations (35, 36, 57).
During tick engorgment, OspA expression by borreliae di-
minishes (15) while expression of other proteins, exemplified
by OspC, increases (51). By the time of B. burgdorferi trans-
mission to hosts, spirochetes in the tick salivary glands express
little or no OspA. This diminished expression of OspA appears
to explain the weak early immune responses to this antigen in
experimental or natural infection following tick-borne infec-
tion (26, 34, 47, 49) or following inoculation with minimal
infectious doses of cultured spirochetes (3, 47). OspA antibod-
ies are sometimes detected in later stages of infection (34, 50),
implying that this antigen may be reexpressed by at least some
spirochetes during infection. For these reasons OspA-specific
antibodies are ineffective in eliminating infection when they
are administered after infection is established by syringe inoc-
ulation (18, 48) or tick bite (15). Additionally, OspA immunity
is circumvented by challenges of in vivo-adapted borreliae in
the form of transplants of skin from infected donors into
OspA-immunized mice (7). OspA immunization has been
shown to mediate killing of spirochetes directly in the midgut
of feeding ticks and therefore has a primary mode of action at
the vector stage (15, 24). To be efficacious, OspA vaccines must
elicit protective levels of antibody that must be maintained
throughout periods of tick exposure in order to block spiro-
chete transmission from the vector.
Vaccines against pathogens other than Borrelia are often
based on in vivo-expressed antigens that boost anamnestic
responses upon infection, potentiate the action of immune
effector cells and complement, and inhibit key virulence mech-
anisms. Many laboratories have examined the vaccine potential
of B. burgdorferi antigens that are immunogenic during infec-
tion and therefore presumably expressed in vivo. OspC is ex-
pressed during infection (37) and elicits protective immunity in
rodents (27, 40, 42). However, OspC-immunized mice appear
not to be protected against challenge with heterologous B.
burgdorferi isolates (41), and in some cases OspC immunization
failed to protect mice against challenge with even homologous
B. burgdorferi isolates (6, 13). OspE and OspF are immuno-
genic during infection, but OspF elicits only partial protection
against tick-borne or low-dose (102 borreliae) intradermal
challenge and OspE is ineffective as a protective immunogen
(38). Other immunogenic in vivo-expressed antigens that have
been evaluated as targets for protection, including 41-kDa
flagellin, P30, P39, P55, P83, IpLA-7, the OspE homolog P21,
and the OspF homolog pG, have thus far failed to show efficacy
in the prevention of infection (14, 14a, 17, 20, 27, 42, 59, 60).
Identification of in vivo-expressed B. burgdorferi antigens that
are capable of eliciting broadly protective immune responses
has remained elusive.
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In mammalian hosts, B. burgdorferi infection is initiated
when the tick vector deposits the spirochetes into the dermis
during feeding. At both initial and later stages of infection, B.
burgdorferi is commonly found in association with collagen
fibers in the extracellular matrix (5, 58). Recent findings (29)
suggest that colonization of these collagenous tissues may be
mediated by spirochetal surface adhesins binding specifically to
the collagen-associated proteoglycan decorin (12). These ad-
hesins were expressed at low-to-moderate copy numbers on
cultured borreliae (29). Genes for two adhesins of B. burgdor-
feri recognizing decorin, lipoproteins with apparent masses of
18 to 20 kDa called decorin binding proteins A and B (DbpA
and DbpB, respectively), have been partially characterized
(28). In the current study, we examined the immunogenicity of
DbpA and DbpB during infection, examined their accessibility
to antibodies and efficacy as potential vaccine candidates, and
evaluated the serological conservation of these proteins.
(This work was presented, in part, at the 14th annual meet-
ing on Modern Approaches to the Control of Infectious Dis-
eases, 9 to 13 September 1996, Cold Spring Harbor Labora-
tory, Cold Spring Harbor, N.Y., and in a preliminary report
[10a] resulting from that meeting.)
MATERIALS AND METHODS
B. burgdorferi isolates. Isolates of B. burgdorferi sensu lato were donated by the
laboratories of A. Barbour, S. Barthold, R. Johnson, J. Leong, and S. Norris or
from the Rocky Mountain Laboratories Microscopy Branch collection. The bi-
ologic and geographic origins of these isolates are listed in Table 1. The molec-
ular typing method described by Postic et al. (39) was used to confirm the
phylogenetic designation of each of these isolates. Spirochetes were propagated
in tightly closed containers at 34°C in modified Barbour-Stoenner-Kelly (BSKII)
medium (1) overlaid with a 5% O2–5% CO2–90% N2 gas mixture. Cell densities
of these cultures were determined by dark-field microscopy at a magnification of
3400. Batches of BSKII were qualified for spirochete propagation and infection
testing by confirming that they supported the growth of 1 to 5 cells of isolate B31.
Infectivity of the B. burgdorferi sensu lato isolates for mice was assessed as
described below. The following isolates used for immunologic protection studies
were determined to have the median infectious dose (ID50) values indicated:
B31, 6 3 101; Sh-2-82, 6 3 102; N40, 3 3 102; 297, 3 3 103; 25015, 6 3 101; HB19,
3 3 103; and CA-3-87, 3 3 101.
Expression and purification of recombinant immunogens. Several recombi-
nant forms of DbpA, schematically represented in Fig. 1, were expressed, puri-
fied, and used for immunologic analyses and immunizations. Molecular cloning
was accomplished by standard methods (46). A library (a gift of Robin Isaacs) of
approximately 2-kb Sau3A I fragments of total genomic DNA from a low-
passage culture of B. burgdorferi 297 was constructed in Lambda Zap II (Strat-
agene Cloning Systems, La Jolla, Calif.), and plaques were plated and blotted
onto nitrocellulose membranes by standard methods (46). Phage was recovered
from plaques binding digoxigenin-conjugated decorin (29), and B. burgdorferi
DNA inserts were excised as clones in the phagemid vector pBluescript II (pBsII)
SK(2) according to the manufacturer’s protocol. One of these clones, recombi-
nant plasmid pBG26 (ATCC 69791), harbored a 2.5-kb B. burgdorferi DNA insert
containing two 561-bp open reading frames (28). Both of these two genes ex-
pressed products with decorin binding activity and were subsequently named
dbpA (GenBank accession no. U75866) and dbpB (GenBank accession no.
U75867). The nucleotide sequences of dbpA and dbpB shared 50% identity.
Single homologs of the dbpA and dbpB genes have been identified recently in the
whole genome sequence of B. burgdorferi B31, residing on the linear plasmid
lp54, which also contains the ospAB operon (25a). The B31 homologs share 94
and 100% similarity, respectively, with the original dbpA and dbpB genes from B.
burgdorferi 297. Recombinant clone pBG29 was constructed from pBG26 by
HindIII partial digestion, with deletion of the 59 half of the dbpB gene and
retaining full-length dbpA and expression of its product. DbpA297 was purified
from Escherichia coli JM101/pBG29 by affinity chromatography on decorin-
conjugated Sepharose. Decorin purified (12) from fetal bovine skin, a kind gift of
L. C. Rosenberg (Montefiore Medical Center, New York, N.Y.), was covalently
linked to CNBr-activated Sepharose 4B (Pharmacia, Uppsala, Sweden) accord-
ing to the manufacturer’s instructions. A 1-liter culture of JM101/pBG29 in LB
medium (46) plus 100 mg of ampicillin per ml was shaken until an A600 value of
0.6 to 0.8 was reached, isopropylthiogalactoside (IPTG) was added to 0.2 mM,
and shaking was continued for 2 to 3 h. Cells were suspended in 10 ml of
phosphate-buffered saline (PBS) and lysed in a French pressure cell, and the
soluble fraction was collected following centrifugation at 200,000 3 g. The
supernatant fluid was passed through a 0.45-mm-pore-size filter, and 5 ml of the
filtrate was passed through a 2-ml decorin-Sepharose column that bound the
DbpA. After the column was washed with 20 ml of PBS, DbpA was eluted from
the column with 1 M NaCl and recovered at .90% homogeneity as judged by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). DbpA
remained soluble after dialysis against PBS. Amino-terminal sequencing showed
that this soluble DbpA retained the leader peptide and was the precursor form
(pre-DbpA297) of the mature lipoprotein.
Posttranslational modification may influence the immunogenicity of some
antigens such as OspA (16, 33, 54, 57). Because posttranslational processing of
pre-DbpA297 expressed by JM101/pBG29 appeared to be inefficient, we con-
structed new vectors, pT7Lpp1 and pT7Lpp2, capable of expressing proteins as
fusions with leader peptides derived from the abundant E. coli lipoprotein Lpp
in order to increase posttranslational processing efficiency. Others had previously
shown that a similar Lpp leader fusion strategy was effective for OspA (30). To
construct pT7Lpp1 the NdeI-EcoRV fragment of pET-30b (Novagen, Inc., Mad-
ison, Wis.) was replaced with a synthetic DNA fragment created by annealing the
oligonucleotides 59-TATGAAAGCTACTAAACTGGTACTGGGCGCGGTA
ATCCTGGGTTCTACTCTGCTGGCAGCATGCGATCAGAT-39 and 59-ATC
TGATCGCATGCTGCCAGCAGAGTAGAACCCAGGATTACCGCGCCCA
GTACCAGTTTAGTAGCTTTCA-39 encoding MKATKLVLGAVILGSTLLA
ACDQ, a modified version of the 59 end of the lpp gene (GenBank accession no.
V00302). A second vector, pT7Lpp2, was created in a similar manner with the
oligonucleotides 59-TATGAAAGCTACTAAACTGGTACTGGGCGCGGTA
ATCCTGGGTTCTACTCTGCTGGCAGGTTGCTCCTCGAT-39 and 59-ATC
GAGGAGCAACCTGCCAGCAGAGTAGAACCCAGGATTACCGCGCCCA
GTACCAGTTTAGTAGCTTTCA-39, encoding the exact sequence of the ami-
no-terminal end of Lpp, MKATKLVLGAVILGSTLLAGCSS. DNA encoding
the entire sequence (28) of the mature DbpA297 protein (GenBank accession no.
U75866), after the cysteine at the site of posttranslational modification, was
amplified from B. burgdorferi 297 template DNA by PCR with oligonucleotide
primers 59-CCGGATCCCGGACTAACAGGAGCAACAAAAATC-39 (the
added BamHI site is underlined) and 59-TGGTCTAAGCTTTTGAGTTGCAT
ATAAAAATGG-39 (the added HindIII site is underlined). After digestion of
PCR products and vector with BamHI and HindIII, the dbpA gene fragment was
ligated into pT7Lpp1 yielding pMSH24. This plasmid expresses chimeric lipopro-
tein Lpp1:DbpA297 that differs from the natural sequence by the vector-added
residues DQISDP between the amino-terminal C and the natural G at DbpA297
position 12 following processing of the leader peptide. E. coli BL21(DE3)/pLysS
(55) was transformed with pT7Lpp1 (negative control for protein expression)
and pMSH24.
BL21(DE3)/pLysS/pMSH24 was grown at 37°C in LB plus 50 mg of kanamycin
per ml and 20 mg of chloramphenicol per ml to mid-exponential phase, protein
expression was induced by the addition of IPTG to 1.0 mM, and after an
additional 2 h of growth, the cells were harvested by centrifugation. The cell
paste was suspended in cold PBS at ;0.25 g (wet weight) of Triton X-114 per ml
(10% [vol/vol] in PBS) was added to 2%, and the cells were lysed by sonication
in an ice bath. After gentle overnight agitation at 4°C, insoluble material was
removed by centrifugation at 100,000 3 g, and the supernatant was decanted.
Cloud point extraction (9) of the Triton X-114 supernatant enriched for the
Lpp1:DbpA297 in the detergent phase. This detergent phase was diluted 20-fold
with 20 mM NaH2PO4 buffer (PB), pH 7.4, containing 1% (wt/vol) 3-[(3-chol-
amidopropyl)dimethylammonio]-1 propane-sulfonate (CHAPS) and loaded
onto a DEAE Sepharose Fast Flow (FF) column. The flowthrough containing
Lpp1:DbpA297 was adjusted to pH 4.0 and applied to an SP Sepharose FF
column. After the mixture was washed with column buffer (PB [pH 4.0]–1%
CHAPS), application of a NaCl step gradient in column buffer resulted in elution
of bound Lpp1:DbpA297 from the column at the 0.5 M NaCl step. Lpp1:
DbpA297-containing fractions were adjusted to neutral pH and concentrated in
a Prodicon (Spectrum Medical Industries, Inc., Houston, Tex.) vacuum concen-
trator against PBS–0.1% CHAPS. Lpp1:DbpA297 was recovered at .95% purity.
DbpAN40 was expressed from pT7Lpp2 as a chimeric lipoprotein with the
addition of a vector-encoded carboxy-terminal extension VDKLAAA
LEHHHHHH to facilitate purification by immobilized metal-affinity chromatog-
raphy. DNA encoding the entire sequence (44) of the mature DbpAN40 protein
after the cysteine at the site of posttranslational modification was amplified from
B. burgdorferi N40 template DNA by PCR with oligonucleotide primers 59-CC
GGATCCCGGATTAAAAGGAGAAACAAA-39 (the added BamHI site is un-
derlined) and 59-CTGTCTAAGCTTAGTCGACGTTATTTTTGCATTTTT
C-39 (the added HindIII and SalI sites are underlined), digested with BamHI and
SalI, and ligated into the comparable sites of pT7Lpp2 to yield plasmid
pWCR129. A Triton X-114 extract of BL21(DE3)/pLysS/pWCR129 was made as
described above and applied to a Ni21-charged ToyoPearl AF-Chelate-650M
(TosoHaas, Montgomeryville, Pa.) column equilibrated with PBS–1.0% CHAPS.
Lpp2:DbpAN40His was eluted from the column with a 0 to 200 mM gradient of
L-histidine in PBS-CHAPS. After concentration, Lpp2:DbpAN40His purity was
estimated at ;90%.
DbpA297, DbpAB31, and DbpB297 were expressed in E. coli M15/pREP4 from
the vector pQE30 (Qiagen, Inc., Santa Clarita, Calif.) as amino-terminal fusions
with the vector-encoded peptide MRGSHHHHHHGS and purified essentially
according to Qiagen protocols. Cloning by PCR amplification, expression, and
purification of His-DbpA297 and His-DbpB297 (28) will be described elsewhere.
The gene fragment encoding DbpAB31 was PCR amplified with the same primers
used for construction of His-DbpA297. The first 10 codons of dbpA and all 20
codons of the dbpB leader peptide were deleted in these constructions.
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For expression of lipoprotein OspA, plasmid pSO3 was constructed by sub-
cloning the NcoI-BclI fragment from pMV251 (54), containing the full-length B.
burgdorferi B31 ospA gene, into the NcoI and BamHI sites of pET-3d (55). After
growth in LB plus 100 mg of ampicillin per ml and 20 mg of chloramphenicol per
ml, lysis, and fractionation of BL21(DE3)/pLysS/pSO3 through the cloud point
extraction step were carried out essentially as for BL21(DE3)/pLysS/pMSH24
described above. The detergent phase containing lipoprotein OspAB31 was di-
luted approximately twofold to a final concentration of 50 mM citrate–10 mM
EDTA–15 mM CHAPS (pH 4.2), and applied to an SP Sepharose FF column.
Elution of the column with a linear pH gradient to pH 5.7 allowed recovery of
lipoprotein OspAB31 at ;90% homogeneity.
Negative-control immunogens for vaccination studies of mice were prepared
by making extracts of each recombinant E. coli host that were comparable to
those used for chromatography of the Dbp recombinant proteins expressed in
these host strains. These were soluble fractions from lysates of JM101/pBsII and
M15/pREP4 and a detergent-phase extract of BL21(DE3)/pLysS/pT7Lpp1.
Recombinant P39 protein was produced to evaluate seroconversion of mice
following B. burgdorferi inoculation or challenge. Oligonucleotide primers 59-A
TGGATCCGAGTGGTAAAGGTAGTCTTGGGAGC-39 (the added BamHI
site is underlined) and 59-AGAGAAGCTTAGTCGACAATAAATTCTTTAA
GAAACTTCTC-39 (the added HindIII and SalI sites are underlined) were
designed based on the sequence (GenBank accession no. L24194) of the B.
burgdorferi Sh-2-82 bmpA gene encoding P39 and used to amplify the entire
mature region of the P39 protein from B. burgdorferi B31 template DNA by PCR.
After digestion with BamHI and HindIII, the P39B31 gene fragment was cloned
into the same two sites of plasmid pGMal-c, a derivative of the maltose binding
protein (MBP) fusion protein expression vector pMal-c (New England Biolabs,
Beverly, Mass.) with a replacement of the multiple cloning site from pMV261
TABLE 1. Evaluation of diverse B. burgdorferi sensu lato isolates for growth inhibition by rabbit preDbpA297 and OspAB31 antisera, for
immunoblot reactivity, and for decorin binding activity
Borrelia isolate Source and origina Decorin bindingactivityd
DbpA antiserum OspA antiserum
Growth inhibition
end point
Immunoblot
reactivityd
Growth inhibition
end point
Immunoblot
reactivityd
B. burgdorferi sensu stricto
B31 I. scapularis, New York 1b 5,120 11 51,200 11
297 CSF, New York 1 5,120 11 51,200 11
Sh-2-82 I. scapularis, New York 11 5,120 11 51,200 11
N40 I. scapularis, New York 11b 12,800 11 51,200 11
JD1 I. scapularis, Massachusetts 11b 800 11 1,600 11
HB19 Blood, United States 6 ,50 6 100 11
3028 Human pus, Texas 1b 50c 11 1,600 11
G39/40 I. scapularis, Connecticut 6 100 6 3,200 11
LP4 Skin (EM), Connecticut 1b 800 11 ,50 11
LP5 Skin (EM), Connecticut 1b 800 11 ,50 11
LP7 Skin (EM), Connecticut 1b 400 11 ,50 11
NCH-1 Skin, United States 1b 50c 11 100 11
ZS7 I. ricinus, Germany 11 ,50 1 400 11
H11 Blood, Italy 1 200 11 400 11
CA-3-87 I. pacificus, California 6 ,50 2 1,600 11
FRED Human, Missouri 2 1,600 1 3,200 11
HBNC Blood, California 6 3,200 6 3,200 11
B. afzelii
PGau Skin (ACA), Germany 11 50c 11 50 11
ACA I Skin (ACA), Sweden 1 ,50 6 ,50 11
M7 I. persulcatus, China 6 1,600 1 ,50 11
IPF I. persulcatus, Japan 2 1,600 6 200 11
BO23 Skin, Germany 11 50c 11 ,50 1
ECM-1 Skin (EM), Sweden 11 50c 11 100 1
B. garinii
PBr CSF, Germany 11 12,800 1 ,50 11
PBi CSF, Germany 11 800 2 ,50 11
B4 91 Skin, Norway 11 ,100 2 ,50 11
G2.22 CSF, Germany 11 ,50 2 ,50 11
Ip90 I. persulcatus, Russia 1 ,50 6 ,50 11
IP89 I. persulcatus, Russia 11 ,50 2 ,50 1
2226 I. persulcatus, China 1 200 6 ,50 11
Fuji P1 I. persulcatus, Japan 11 100 11 ,50 11
20047 I. ricinus, France 11 50c 6 ,50 11
B. japonica HO14 I. ovatus, Japan 1 ,50 6 50 1
Group 25015 25015 I. scapularis, United States 2 10 6 6,400 11
B. andersonii 21038 I. dentatus, United States 11 1,600 1 ,50 11
a Isolates were derived from patients with Lyme disease or Ixodes tick species. CSF, cerebrospinal fluid; EM, erythema migrans; ACA, acrodermatitis chronicum
atrophicans.
b Two decorin binding bands at 18 to 20 kDa.
c Partial reduction in the number of cells at lowest dilution tested.
d Reactivities were scored on a scale from “2” to “11,” with “2” representing background reactivity comparable to background obtained with nonimmune serum
or immune serum against an irrelevant antigen and “11” representing the strongest specific signal observed. For decorin blotting, “2” represented reactivity
comparable to background obtained in the absence of digoxigenin-conjugated decorin.
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(54). After transformation of the resulting plasmid, pNKP2, into E. coli DH5a,
MBP-P39B31 fusion protein was expressed and purified essentially according to
the manufacturer’s protocols. As a negative protein control reagent, MBP was
purified from DH5a/pGMAL-c in a similar manner.
Antibody reagents. Antisera were raised against recombinant preDbpA297 and
His-DbpB297 in New Zealand White rabbits. Antisera were also generated in
rabbits against recombinant B. burgdorferi B31 OspA lipoprotein purified from
the E. coli clone containing plasmid pOA1 (16) and against recombinant pneu-
mococcal surface protein A (PspA) purified from the E. coli clone containing
plasmid pJY4306 (62). The predicted sequences of the lipoprotein OspA’s ex-
pressed by plasmids pOA1 and pSO3 are identical, but their products used for
mouse and rabbit immunizations, respectively, were purified by different chro-
matographic procedures. Each animal received a primary subcutaneous (s.c.)
immunization of 200 mg of protein emulsified with complete Freund’s adjuvant
(CFA), followed by two or three booster injections of 100 mg with incomplete
Freund’s adjuvant (IFA) at 3- to 4-week intervals. Titers of rabbit sera against
their homologous recombinant borrelial antigens were 128,000 to 256,000 by
enzyme-linked immunosorbent assay (ELISA). Rabbit anti-His-DbpB297 reacted
weakly with pre-DbpA297 (titer of 4,000), but reactivity of rabbit anti-pre-
DbpA297 with His-DbpB297 was at background levels. These proteins were pre-
viously observed to have minimal serologic cross-reactivity (28) consistent with
their limited sequence homology (40% amino acid identity and 56% similarity).
Monoclonal antibody (MAb) H5332 (2) against OspA, an immunoglobulin G1
(IgG1), was a gift of Alan Barbour. The DbpA-specific MAb 7D2B.3G6, an
IgG2b, was obtained from a cloned hybridoma of splenic B cells from preDbpA-
immunized BALB/cByJ (BALB; The Jackson Laboratory, Bar Harbor, Maine)
mice fused with P3X63Ag8U.1 myeloma cells by standard methods (61).
Antisera against Lpp1:DbpA297 and OspAB31 were also obtained, prior to
challenge, from C3H/HeJ (C3H; Jackson Laboratory) mice immunized (see
below) for use in protection experiments (Table 2, experiment D, groups 2 and
3) and used for scanning immunoelectron microscopy and evaluation of passive
immunization.
Scanning immunoelectron microscopy. In vitro-passage-5 B. burgdorferi B31
was collected from 0.5 ml of a mid-log-phase culture by centrifugation for 5 min
FIG. 1. Diagrammatic representation of the recombinant Dbp immunogens
evaluated for vaccine efficacy. All proteins included the complete DbpA or DbpB
coding sequence following Cys at the site of the presumed posttranslational
processing. Lpp1:DbpA297 is a fusion of this mature DbpA protein sequence to
a modified lpp leader peptide. Fusions of DbpA and DbpB to a (His)6 tag were
made within, or in place of, their respective leader peptides. Lpp2:DbpAN40His
has both a N-terminal lpp leader and a C-terminal (His)6 fusion.
TABLE 2. Protection of mice by active immunization with different forms of DbpA compared with that by immunization with OspA
Expt (mouse strain/
challenge isolate) Mouse group Immunogen
a
No. of positive cultures/total
no. tested P39 IgGb No. of mice infected/total no.
Bladder Ear Joint
A (C3H/297) 1 His-DbpA297 0/5 0/5 0/5 0/5 0/5
2 Lpp1:DbpA297 0/5 0/5 0/5 0/5 0/5
3 OspAB31 0/5 0/5 0/5 2 0/5
4 PBS 5/5 5/5 4/5 1 5/5
B (C3H/N40) 1 Lpp2:DbpAN40His 0/5 0/5 0/5 0/5 0/5
2 OspAB31 5/5 0/5 0/5 1 5/5
3 E. coli BL21 (det.) 4/4 4/4 1/4 1 4/4c
4 None 5/5 5/5 5/5 1 5/5
Cd (BALB/B31) 1 Pre-DbpA297 0/5 0/5 0/5 0/5 0/5
2 OspAB31 0/5 0/5 0/5 2 0/5
3 E. coli JM101 (sol.) 5/5 5/5 5/5 ND 5/5
4 None 5/5 5/5 5/5 1 5/5
(C3H/B31) 5 Pre-DbpA297 5/5 0/5 0/5 5/5 5/5
6 OspAB31 0/5 0/5 0/5 2 0/5
7 E. coli JM101 (sol.) 5/5 5/5 5/5 ND 5/5
8 None 5/5 5/5 5/5 1 5/5
D (C3H/B31) 1 Pre-DbpA297 5/5 0/5 0/5 5/5 5/5
2 Lpp1:DbpA297 5/5 0/5 0/5 5/5 5/5
3 OspAB31 0/5 0/5 0/5 2 0/5
4 E. coli JM101 (sol.) 5/5 5/5 5/5 1 5/5
5 E. coli BL21 (det.) 5/5 5/5 5/5 1 5/5
6 None 5/5 5/5 5/5 1 5/5
Ed (C3H/B31) 1 Pre-DbpA297 3/5 0/5 0/5 3/5 3/5
2 His-DbpA297 1/5 0/5 1/5 1/5 1/5
3 His-DbpAB31 1/4 0/4 0/4 0/4 1/4
c
4 OspAB31 0/5 0/5 0/5 0/5 0/5
5 E. coli M15 (sol.) 5/5 5/5 5/5 ND 5/5
6 None 5/5 5/5 5/5 5/5 5/5
a Immunogen doses were 20 mg for DbpA, 5 mg for OspA, and 5 mg for E. coli soluble (sol.) and detergent (det.) extracts, except 20 mg in experiment C.
b Presence of IgG to P39 at the time of sacrifice was determined for most groups of mice (number positive/number tested). When sera were assayed as pools, the
presence or absence of P39 IgG was scored as 1 or 2, respectively. ND, not determined.
c Data were not recorded for one mouse in groups B3 and E3 that died prior to challenge.
d Data for experiments C and E are reproduced from Vaccines ’97 (10a) with permission of the publisher.
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at 1,000 3 g. Sedimented cells were gently resuspended in 0.2 ml of BSKII
containing 12 ml of immune or preimmune mouse serum and incubated for 30
min at room temperature with mixing. Spirochetes were then collected by cen-
trifugation and washed twice in BSKII. The bacteria were labeled by incubation
in 0.2 ml of BSKII containing 16 ml of goat anti-mouse IgG plus IgM conjugated
to 30-nm-diameter gold particles (Ted Pella, Inc., Redding, Calif.). Labeled
spirochetes were collected and gently washed twice in Tyrode’s buffer and al-
lowed to settle onto 0.1% poly-1-lysine-coated coverslips. After 10 min, the
buffer was replaced with fixative containing 2.5% glutaraldehyde in 0.2 M sodium
cacodylate (pH 7.2). Following fixation, the coverslips were washed twice in
cacodylate and postfixed in 1% osmium tetroxide in cacodylate. After being
washed in water and dehydrated in ethanol, the samples were critical-point dried
from ethanol through carbon dioxide, lightly sputter coated with chromium, and
observed with a Hitachi S4500 field emission scanning electron microscope
equipped with an ultralow-voltage backscattered electron detector (GW Elec-
tronics, Norcross, Ga.).
Immunization of mice and challenge with B. burgdorferi. For passive immuni-
zations, undiluted rabbit antiserum, or antiserum diluted in PBS, was adminis-
tered intraperitoneally (i.p.) to 6- to 8-week-old female C3H mice within 1 h
prior to challenge (day 0) or at various times afterward. For active immuniza-
tions, C3H or BALB mice were injected i.p. at week 0 with 20 mg of DbpA or
DbpB, 5 mg of OspA, 20 or 5 mg of soluble or detergent extract of E. coli or PBS
emulsified with CFA, given a similar booster immunization in IFA at week 4, and
challenged at week 6. B. burgdorferi spirochetes were diluted in BSKII from
exponentially growing cultures, and mice were injected s.c. at the base of the tail
with 0.1 ml of these dilutions (typically 104 borreliae unless noted otherwise).
Isolates used for challenge were passaged fewer than six times in vitro. To assess
infection, mice were sacrificed at 14 to 17 days postchallenge, and specimens
derived from ears, urinary bladders, and tibiotarsal joints were placed in BSKII–
1.4% gelatin–13 mg of amphotericin B per ml–1.5 mg of phosphomycin per ml–15
mg of rifampin per ml, and borrelial outgrowth at 2 or 3 weeks was assessed by
dark-field microscopy. Mice were scored as infected when any of the three tissues
were culture positive. In some instances, seroconversion for protein P39 reactiv-
ity was also used to confirm infections (see below). Median effective dilutions
(ED50) of passively administered antisera and ID50 of borreliae were assessed in
groups of three C3H mice per dose and were calculated by a standard method
(43). Immune serum was also obtained from C3H mice persistently infected with
B31.
In vitro growth inhibition assay. A microwell antibody titration assay (45) was
used to evaluate the growth inhibition properties of antisera for various isolates
of B. burgdorferi sensu lato. Briefly, 105 spirochetes in 100 ml of BSKII were
added to serial twofold dilutions of antisera in 100 ml of BSKII in 96-well plates,
and the plates were covered and incubated at 34°C in a 5% O2–5% CO2–90% N2
gas mixture for 72 h prior to quantification of borrelia growth by dark-field
microscopy. The highest serum dilution showing growth inhibition of .90%
reduction in the number of cells and motility was designated as the end point
growth inhibition titer. Since, in most cases, antisera diluted less than 1:100 gave
only partial growth inhibition, a titer of $100 was defined as positive inhibition.
Immunoblotting and decorin blotting. In a single-well format, samples (2 mg)
of Lpp1:DbpA297, OspAB31, or MBP-P39B31 were boiled in sample buffer con-
taining 1% SDS–2.5% 2-mercaptoethanol before SDS-PAGE through 3% stack-
ing and 12.5% acrylamide resolving gels. Gels were electroblotted onto nitrocel-
lulose membranes, and lanes were probed with 1:50 dilutions of immune sera
from infected mice or 1:2,000 dilutions of purified MAbs, followed by the ap-
propriate secondary antibody-enzyme conjugate. Membranes used for DbpA and
OspA comparative immunogenicity studies were stained with Ponceau S to
confirm that equivalent amounts of purified protein had transferred following
electroblotting. Immunoblot signals were detected by fluorography with ECL
chemiluminescence reagents (Amersham Corp., Arlington Heights, Ill.).
Assay of decorin binding activity was performed essentially as described by
Guo et al. (29). Briefly, spirochetes were harvested from culture by centrifuga-
tion, washed once with 10 mM HEPES (pH 7.4)–20 mM NaCl, and suspended to
1 3 107 to 5 3 107 cells/ml in SDS–2-mercaptoethanol sample buffer. Samples of
spirochetes were subjected to SDS-PAGE as described above, electroblotted to
nitrocellulose, and probed with digoxigenin-conjugated decorin (29) followed by
antidigoxigenin secondary antibody-enzyme conjugate (Genius System; Boehr-
inger Mannheim Corp., Indianapolis, Ind.). Antidigoxigenin signals were de-
tected by fluorography following incubation of the filters with Lumi-Phos 530
(Boehringer Mannheim).
Reactivities were scored on a scale from “2” to “11,” with “2” representing
background reactivity comparable to background obtained with nonimmune
serum or immune serum against an irrelevant antigen and “11” representing
the strongest specific signal observed. For decorin blotting, “2” represented
reactivity comparable to background obtained in the absence of digoxigenin-
conjugated decorin.
ELISA. Wells of 96-well microtiter plates (Immulon 2; Dynatech, Chantilly,
Va.) were coated with antigen by incubating 50 ml of a 1-mg/ml antigen solution
in 0.1 M sodium carbonate buffer at pH 9.6. After unbound antigen was de-
canted, additional binding sites were blocked by incubating 200 ml of 3% nonfat
milk in wash buffer (PBS–0.2% Tween 20 [pH 7.4]). After washing, duplicate
serial twofold dilutions of sera in PBS–Tween 20–1% fetal bovine serum were
incubated for 1 h and removed, and the wells were washed three times. The wells
were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG or
goat anti-rabbit IgG, as appropriate. After three washes, bound antibodies were
detected with H2O2 and 2,29-azino-di-(3-ethylbenzthiazoline-6-sulfonate)
(ABTS; Kirkegaard & Perry, Gaithersburg, Md.), and A405 was quantified with a
Molecular Devices Corp. (Menlo Park, Ca.) Vmax plate reader. IgG levels that
were less than or equal to twice the background level in serum samples from
naive mice or rabbits were assigned the minimum titer of 1:100 or 1:500, respec-
tively.
RESULTS
DbpA is surface accessible. Determination of the subcellular
location of B. burgdorferi proteins is complicated by the chem-
ical and mechanical fragility of the spirochetal outer mem-
brane (13). We used scanning immunoelectron microscopy to
evaluate the location of DbpA and OspA on in vitro-grown
unfixed B. burgdorferi sensu stricto isolate B31 and to confirm
the integrity of the antibody-labeled cells. Antibodies against
both DbpA and OspA bound to the surface of intact borreliae
(Fig. 2). Anti-DbpA labeling was uniformly scattered along the
spirochete surface (Fig. 2A). Occasionally spirochetes (fewer
than 1 in 10) were observed to label heavily with anti-DbpA,
suggesting variability in the expression or the accessibility of
this protein among cells in this population (Fig. 2B). Anti-
OspA labeling was typically more dense and tended to occur in
aggregates, possibly reflecting antibody cross-linking of these
target proteins (Fig. 2C). The heavier labeling of OspA was
consistent with analyses by SDS-PAGE indicating that in vitro
OspA levels were 5- to 10-fold-higher than DbpA (29) (data
not shown). Periplasmic endoflagella, which are normally con-
tained within the spirochetal outer membrane, did not pro-
trude from these antibody-labeled cells, leading us to tenta-
tively conclude that these membranes were intact and that
DbpA and OspA were surface exposed. Endoflagellar fila-
ments were observed protruding from other cells that were
partially disrupted (data not shown). These observations do
not preclude the possibility of additional quantities of these
FIG. 2. Detection of surface-directed antibody labeling by scanning immu-
noelectron microscopy. B. burgdorferi B31 was incubated in BSKII plus mouse
anti-DbpA (A and B), mouse anti-OspA (C), or normal mouse serum (D) prior
to labeling of bound antibodies with goat anti-mouse IgG plus IgM-conjugated
colloidal gold particles. Typical electron micrographs for these samples are
shown except for panel B, which represents spirochetes with atypically heavy
anti-DbpA labeling. Bars, 0.2 mm.
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lipoproteins at a subsurface location, as suggested by others
(13).
Infection elicits strong antibody responses against DbpA
and DbpB but not OspA. Dermal inoculation with low num-
bers of B. burgdorferi organisms near the ID50 failed to elicit
antibody responses to OspA but did elicit antibodies to other
proteins early in the infection (3, 47). It has been proposed that
such inoculations approximate the number of borreliae deliv-
ered by tick bites (47). We examined the kinetics and level of
the antibody response of C3H mice to DbpA following s.c.
inoculation with 102, 103, or 104 B31 spirochetes. Isolate B31
(uncloned) was chosen because it was one of the most infec-
tious isolates and could be consistently cultured from multiple
tissues (including bladder, ear, and joint) of infected mice.
Three of 10 mice inoculated with 102 B31 became infected, and
all mice were infected at the higher doses. Sera from infected
mice within each dose group were pooled and analyzed for
immune responses to specific borrelial proteins. Antibodies
reactive with DbpA were detectable by immunoblotting within
2 weeks of infection with 102 borreliae, while OspA-specific
antibodies remained at background levels within the first 8
weeks after infection (Fig. 3). Sera from culture-negative mice
in the 102 dose group did not react with DbpA or OspA (data
not shown), indicating that the amount of these proteins in 102
borreliae was subimmunogenic and suggesting that DbpA im-
mune responses were against antigens synthesized in vivo dur-
ing spirochete multiplication. At inoculum doses of 103 and 104
spirochetes, early IgG responses to both DbpA and OspA were
observed, but anti-DbpA responses were strongest. This was
particularly evident at 8 weeks, when anti-OspA reactivity
waned and responses to DbpA increased (lanes 9 and 12).
Transient anti-DbpA IgM was detectable at all inoculum
doses, but anti-OspA IgM responses were much weaker rela-
tive to background (lane 3) and were detectable only at inoc-
ulum doses of 103 and 104 spirochetes (lanes 8 and 11).
We extended serologic analysis to include antibody reactivity
to DbpB and the lipoprotein P39 (BmpA), as well as DbpA
and OspA, using an ELISA and serum pools from mice with
culture-verified infection collected at intervals after inocula-
tion with 102 B31 spirochetes. Others have previously shown
that mice elicited antibodies to P39 when inoculated with live
borreliae by syringe or tick bite but not with killed borreliae
(52). At nearly every time point, the relative reactivity of an-
tibodies against DbpA was greater than that against DbpB,
which in turn was greater than antibody reactivity against P39
(Fig. 4). Antibody reactivity against OspA was near back-
ground (i.e., MBP) during early infection but rose somewhat at
later times.
Passive immunization of mice with DbpA and DbpB anti-
sera. As we initially lacked an isolate of B. burgdorferi 297 that
was infectious for mice, isolate B31 was chosen for our first
protection studies since it was found to be sensitive to killing in
vitro by both preDbpA and OspA antisera (Table 1). Addi-
tionally, we sought to determine if antiserum against DbpA
would passively protect mice against challenge with a heterol-
ogous B. burgdorferi sensu stricto isolate. Rabbit antiserum
FIG. 3. Early antibody responses to DbpA and OspA elicited by low-dose
challenge. Multilane immunoblot showing antibodies reactive with DbpA and
OspA at weeks 2, 4, and 8 postchallenge (lanes 4 to 12) in sera pooled from mice
infected by challenge with 102, 103, or 104 B. burgdorferi (B.b.) B31 spirochetes.
Lanes: 1, anti-DbpA MAb, 1.0 mg/ml; 2, anti-OspA MAb, 0.2 mg/ml; 3, normal
mouse serum. Samples for SDS-PAGE were 2 mg of purified Lpp1:DbpA297 or
OspAB31.
FIG. 4. Relative levels of IgG antibodies to DbpA, DbpB, and other selected
borrelial antigens during chronic infection of mice. Sera were collected for a
1-year period from mice infected by challenge with 102 B31. Sera were pooled at
each time point, and end point titers of IgG specific for each of four recombinant
borrelial antigens were determined by ELISA. E. coli MBP, the fusion partner
for recombinant P39, was used as a negative control protein.
TABLE 3. Relative potencies of rabbit pre-DbpA297 and OspAB31 antisera for passive protection of C3H mice from challenge with
B. burgdorferi B31
Antiserum (0.1-ml dose) Day(s) of antiserumadministration
No. of mice infected for serum dilution of:
ED50
None (undiluted) 1:5 1:25 1:125
Pre-DbpA297 0 0/3 1/3 2/3 3/3 1:11.2
0, 2 0/3 0/3 0/3 2/3 1:83.1
OspAB31 0 0/3 1/3 3/3 ND
a 1:7.5
0, 2 0/3 1/3 3/3 ND 1:7.5
a ND, not determined.
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against pre-DbpA297 and antiserum against OspAB31 were pas-
sively administered at the time of challenge with 104 B. burg-
dorferi B31 spirochetes. Undiluted, both antisera protected
mice from infection (Table 3; data not shown). The ELISA
IgG titers of the rabbit pre-DbpA297 and OspAB31 antisera
against their homologous recombinant antigens were compa-
rable (;256,000). When 0.1 ml of antiserum was given at the
time of challenge, the ED50 values of the DbpA and OspA sera
were comparable (1:11.2 versus 1:7.5). A second administra-
tion of OspA serum on day 2 had no effect, whereas a second
administration of DbpA antiserum was much more effective
than the single treatment on day 0 (Table 3). It is noteworthy
that the higher ED50 for the anti-DbpA297 serum, relative to
the anti-OspAB31 serum, was obtained with the B31 isolate,
which was heterologous to the DbpA297 antigen. Passive im-
munization of C3H mice with rabbit His-DbpB297 antiserum
(ELISA IgG titer of 128,000) showed only partial protection
against challenge with 104 B. burgdorferi B31 spirochetes (two
mice protected of five) and no protection against challenge
with 104 B. burgdorferi N40 spirochetes (no mice protected of
five). Passive immunization against DbpB was not evaluated
further in this study.
Elimination of infection by postinoculation administration
of DbpA, but not OspA, antisera. Passive protection results
suggested that DbpA may be accessible to antibodies for
longer than OspA after challenge and that these relative
changes in protein expression or accessibility happen in peri-
ods as short as 2 days. The possibility that DbpA is a target for
protective antibodies after OspA is no longer accessible was
addressed further by administering antisera against both of
these antigens to mice at increasing intervals after challenge
(Table 4). Cohorts of 30 or 36 C3H mice were inoculated with
104 B. burgdorferi B31 spirochetes, and then groups of three
mice each received antisera starting at 0, 2, 4, 5, 6, 7, or 10 days
later. In two separate experiments, passive transfer of rabbit
pre-DbpA297 antiserum completely protected mice from infec-
tion with B. burgdorferi B31, even when serum administration
was delayed as long as 4 days but not 5 or more days postin-
oculation. OspAB31 antisera were protective when adminis-
tered at the time of challenge, but not at later times, similar to
observations of others (48). Our observations showed that
DbpA, unlike OspA, was a target for antibody-mediated elim-
ination of borreliae during the early stage of infection and
provided further evidence that the relative in vivo levels or
accessibility of DbpA and OspA change during this period.
Active immunization of mice with DbpA protects against
infection. C3H and BALB mice were actively hyperimmunized
with three forms of recombinant DbpA297 differing only at
their amino termini, one form of DbpAB31, and one form of
DbpAN40 and then challenged with both homologous and het-
erologous B. burgdorferi sensu stricto isolates (Table 2). Immu-
nizations with DbpA or OspA preparations elicited high titers
of serum IgG (ELISA end point titers were .105). C3H mice
immunized with either His-DbpA297 or Lpp1:DbpA297 were
protected from challenge with the homologous 297 isolate as
judged by culture and P39 seroconversion (experiment A).
C3H mice immunized with Lpp2:DbpAN40His were protected
against N40 homologous challenge (experiment B). However,
OspAB31 did not confer protection against the heterologous
N40 challenge (experiment B). BALB mice immunized with
pre-DbpA297 were protected from challenge with the heterol-
ogous B31 isolate (experiment C), but protection of C3H mice
from B31 challenge by immunization with the various forms of
DbpA was less complete (experiments C, D, and E). Although
protection of C3H mice against B31 challenge was somewhat
higher in one experiment with His-tagged versions of DbpA
(experiment E), more-extensive studies are required to deter-
mine whether this form of the immunogen elicits a more po-
tent immune response in mice. Preliminary experiments com-
paring immunizations with 5 or 20 mg His-DbpA indicated that
fewer mice were protected by the lower DbpA dose (2 of 5
protected at 5 mg versus 4 of 5 at 20 mg). Using Freund’s
adjuvants, we did not observe any substantial difference in
immunogenicities between the acylated Lpp1:DbpA297 and
nonacylated pre-DbpA297 and His-DbpA297. Such differences
may be more apparent with other adjuvants that are clinically
relevant, as has been observed for OspA (2, 16, 33).
In almost every DbpA-immunized mouse where infection
(positive bladder culture and P39 IgG) was observed, infection
of ear and joint tissues was below detectable levels (Table 2).
Unlike borreliae cultured from naive or sham-immunized
mice, spirochetes recovered from bladders of the DbpA-im-
munized C3H mice were elongated and morphologically irreg-
ular, had reduced motility, and became nonviable before ex-
ceeding 106 cells/ml. We were unable to propagate sufficient
quantities of these spirochetes to permit further physiological
or genetic analyses.
As was the case with passive immunization against DbpB,
only partial protection against challenge with 104 B. burgdorferi
B31 spirochetes was achieved by active immunization of mice
with His-DbpB297. Three of five BALB mice were protected,
but all five C3H mice immunized with His-DbpB297 were in-
fected at multiple sites.
Passive immunization of mice against diverse B. burgdorferi
sensu stricto isolates. We next compared the abilities of rabbit
DbpA and OspA antisera to protect C3H mice against chal-
lenge with five B. burgdorferi sensu stricto isolates and isolate
25015, which is classified as phylogenetically distinct by some
typing methods (10, 39), to assess the conservation of protec-
tive epitope(s) on these antigens (Table 5). Antiserum against
pre-DbpA297 protected C3H mice against challenge with the
three genetically heterologous B. burgdorferi sensu stricto iso-
lates B31, Sh-2-82, and N40. Significantly, DbpAN40 shares
only 67% amino acid sequence identity (75% similarity) with
DbpA297 (44), demonstrating broad reactivity of rabbit DbpA
antiserum. Pre-DbpA297 antiserum gave broader protection
than anti-OspAB31 serum against these isolates (Table 5). Iso-
lates 25015, HB19, and CA-3-87 were resistant to both pas-
sively administered pre-DbpA297 and OspAB31 antisera. With
TABLE 4. Postchallenge administration of rabbit pre-DbpA297
antiserum aborts infection of B. burgdorferi B31
Expt no.a Antiserum
No. of mice infected on day
0 2 4 5 6 7 10
1 Pre-DbpA297 0/3 0/3 0/3 ND
b ND 3/3 3/3
OspAB31 0/3 3/3 3/3
PspAc 3/3
None 3/3
2 Pre-DbpA297 0/3 0/3 0/3 3/3 3/3 3/3 3/3
OspAB31 0/3 3/3 3/3
PspA 3/3
None 3/3
a In experiment 1, mice were given a single passive administration of rabbit
antiserum (0.1 ml i.p.) at the time of challenge (day 0) or on one of several
intervals afterward. On day 17, mice were sacrificed and evaluated for infection.
Data are reproduced from Vaccines ’97 (10a) with permission of the publisher.
In experiment 2, serum was given in two 0.05-ml doses 48 h apart, starting at the
interval indicated.
b ND, not determined.
c PspA, pneumococcal surface protein A, irrelevant immunogen.
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respect to OspA heterogeneity, the lack of cross-protection
between OspA of B. burgdorferi sensu lato isolate 25015 and
OspA from a B. burgdorferi sensu stricto isolate (N40) has
previously been observed by others (21).
Conservation of DbpA epitope(s) binding growth-inhibitory
antibodies. We next examined a large panel of B. burgdorferi
sensu lato isolates with diverse geographic and biologic origins
and representing six of the major phylogenetic groups (10, 39,
53) using a microwell-based growth inhibition assay (45) and
by immunoblotting to evaluate the in vitro expression and
serologic conservation of DbpA and OspA among these iso-
lates (Table 1). To supplement immunoblotting, we also used
a decorin blot assay (29) to evaluate expression of DbpA and
DbpB. Sensitivities of these isolates to growth inhibition by
rabbit pre-DbpA297 or OspAB31 antisera were assessed in par-
allel. Growth of 19 of the 35 B. burgdorferi sensu lato isolates
(54%) was inhibited (defined as growth inhibitory titer of
$100) by pre-DbpA297 antiserum. This growth-inhibitory ef-
fect did not require addition of serum complement, similar to
observations by others using this assay (45). Most isolates of B.
burgdorferi sensu stricto (12 of 17 [71%]) and nearly half of the
isolates of B. afzelii (2 of 6) and B. garinii (4 of 9) were inhibited
by pre-DbpA297 antiserum (range of inhibitory titers, 100 to
12,800). In some cases resistance to DbpA antiserum corre-
lated with weak or negative reactions by immunoblotting and
decorin blotting (HB19, CA-3-87, and 25015); these isolates
apparently expressed little or no DbpA in vitro although PCR
analysis indicated that each isolate contained a dbpA gene
homolog (44). Some B. garinii isolates were inhibited weakly,
or not at all, by pre-DbpA297 antiserum but were positive by
decorin blotting (PBi, B4 91, G2.22, and IP89). Isolate PBi was
inhibited by pre-DbpA297 antiserum but was negative by im-
munoblotting. For a few isolates (FRED and IPF), decorin
binding activity appeared to be lost after SDS-PAGE, yet the
isolates remained immunoreactive. Possibly differences in
DbpA in vitro expression levels, in epitope structure, and in
antibody accessibility, all contributed to differences in anti-
DbpA inhibitory end point titers among these isolates. About
half of the isolates (17 of 35 [49%]) were inhibited by OspAB31
antiserum (range of inhibitory titers, 100 to 51,000) even
though all 35 isolates were positive for OspA expression by
immunoblotting. The OspAB31 antiserum had negligible inhib-
itory activity against the nine B. garinii isolates. Thus, DbpA
epitopes capable of binding growth-inhibitory antibodies ap-
peared to be as conserved as, if not more conserved than, those
of OspA. Most of the isolates (26 of 35 [74%]) were inhibited
by at least one of the two antisera, suggesting that combina-
tions of these two antigens might provide broader vaccine
coverage than either one alone.
Rabbit His-DbpB297 antiserum was also tested for in vitro
growth inhibition activity. This antiserum had negligible effect
on the in vitro growth of B. burgdorferi B31, Sh-2-82, and N40
(data not shown); therefore, this analysis was not expanded
further. However, all three isolates were positive for DbpB
expression by immunoblotting (data not shown), demonstrat-
ing that they expressed DbpB in vitro.
DISCUSSION
Many proteins of B. burgdorferi, including Osps A-F, 41-kDa
flagellin, IpLA-7, P21, P30, P35, P37, P39, P55, P83, pG, and
lp6.6, have been evaluated as targets for protection in animal
models of Lyme borreliosis (14–17, 19–24, 27, 33, 36, 38, 40–42,
48, 54, 59, 60). Among these, only antibodies to OspA, OspB,
and OspC have been shown to prevent infection completely.
Combined administration of antisera against two in vivo-ex-
pressed proteins, P35 and P37, 1 day after homologous chal-
lenge also provided protection in a recent study (22) but only
against 102, but not 104, spirochetes. The duration of P35/P37
target accessibility beyond day 1, or the level of serologic con-
servation of these antigens, was not reported. We show here
that DbpA is accessible to antibodies capable of aborting in-
fection up to 4 days after inoculation and is serologically cross-
reactive among many borrelial isolates. In contrast, antibodies
to OspA were ineffective at aborting established infection, as
previously reported by others (48).
DbpA and DbpB are relatively minor proteins of cultured B.
burgdorferi compared to OspA (28, 29). The antigenic stimulus
provided to mice by a minimal infectious dose (102) of B.
burgdorferi B31 was insufficient to elicit immune responses to
these proteins in mice that failed to become infected, but
persistent and high titers of DbpA and DbpB antibodies, and
not OspA antibodies, were observed in culture-positive mice.
These observations provide evidence that DbpA and DbpB are
expressed in vivo during infection.
DbpA antibodies bound specifically to the surface of intact
cultured spirochetes (Fig. 2) and were able directly to inhibit
the growth of B. burgdorferi both in vivo and in vitro (Tables 1,
2, and 5). Similar observations were also made for OspA an-
tibodies. However, the experiments evaluating the postchal-
lenge protective efficacies of these antibodies were able to
distinguish major differences in the expression level or surface
accessibility of OspA, relative to that of DbpA, during the first
4 days after dermal inoculation of spirochetes (Tables 3 and 4).
This decrease in expression or accessibility of OspA can be
taken as evidence that the spirochetes are undergoing a host
adaptation process at this stage of the infection. Methods ca-
pable of directly demonstrating the in vivo surface accessibility
of B. burgdorferi outer membrane components are not cur-
rently available. The observation that B. burgdorferi remains
sensitive to the growth-inhibitory effects of DbpA antiserum
after a 4-day period of host adaptation provides evidence that
DbpA, and not OspA, is surface accessible in vivo during this
stage of infection. This is the first report demonstrating evi-
dence of in vivo surface accessibility of a defined target in this
manner. In order for decorin adherence (29) to play a role in
TABLE 5. Comparison of pre-DbpA297 and OspAB31 antiserum for
protection of mice against challenge with heterologous
B. burgdorferi isolates
Expt no. and B. burgdorferi sensu
lato challenge isolatea
No. of mice infectedb
DbpA
antiserum
OspA
antiserum No serum
1
B31 0/5 0/5 5/5
Sh-2-82 0/5 1/5 5/5
N40 0/5 5/5 5/5
2
B31 0/5 0/5 5/5
25015 5/5 5/5 5/5
3
B31 0/5 0/5 5/5
HB19 5/5 5/5 5/5
CA-3-87 5/5 5/5 5/5
a Challenge dose with HB19 was 105 borreliae; the challenge dose with other
isolates was 104.
b Rabbit pre-DbpA297 or OspAB31 antiserum (0.05 ml) was administered 1 h
before challenge (day 0) and again on day 2 postchallenge. Data are reproduced
from Vaccines ’97 (10a) with permission of the publisher.
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the virulence of B. burgdorferi, decorin binding proteins would
presumably require in vivo surface exposure.
Others have shown that passive transfer of immune sera
from persistently infected mice to naive mice will eliminate
spirochetes in newly infected mice at 4 days postinfection but
will not eliminate infection when immune serum is adminis-
tered at 12 days postinfection (4). Antigenic targets for this
effect have not been identified, but DbpA may be such a target.
In the present study, spirochetes remained sensitive to the
effects of DbpA antiserum through the first 4 days of infection
in mice but became resistant to DbpA antiserum administra-
tions at later times. Several mechanisms for this resistance are
possible: (i) DbpA expression becomes down-regulated during
or after infection; (ii) DbpA becomes inaccessible on the spi-
rochete to antibodies; or (iii) spirochetes are sequestered in
cells or tissues inaccessible to antibodies. A model suggesting
that surface-exposed lipoproteins may be globally down-regu-
lated in vivo by spirochetes or differentially localized during
infection as part of the host adaptation process has been re-
cently proposed (13). Our observations are consistent with this
model but suggest that this may happen in a stage-specific or
tissue-specific manner and that changes in lipoproteins occur
in a programmed, rather than global, fashion since OspA and
DbpA lipoproteins appeared to lose antibody-mediated vul-
nerability at different times during early infection (Table 4). In
C3H mice the dissemination of B. burgdorferi from the site of
dermal inoculation by syringe begins about 3 to 4 days post-
inoculation (8). This coincides with the time at which DbpA
antibodies were no longer effective at aborting infection in the
present studies. For instance, decorin adherence may contrib-
ute to establishing localized infection in collagen-rich connec-
tive tissues yet may be dispensable during spirochete dissemi-
nation. B. burgdorferi shows tropism for the skin of infected
animals (5, 8), and cutaneous manifestations of human Lyme
borreliosis are seen in both early and late disease (53). Im-
mune response-mediated disease resolution has been observed
in the immunocompetent mouse model of Lyme disease (3, 4)
and has been interpreted to explain intermittent remissions
during human Lyme disease. Anti-DbpA responses may con-
tribute to these effects and to the control of persistent infec-
tion. The sustained anti-DbpA, as well as DbpB and P39, IgG
levels in persistently infected mice may be a result of an im-
mune stimulus by spirochetes when they periodically exit a
putative immunity-privileged niche and ultimately become
eliminated by the host’s immune response.
Active immunization of C3H mice with DbpA conferred
complete, or nearly complete, protection against challenge
with 104 spirochetes of the isolate homologous to the immuno-
gen. Immunization with DbpA conferred complete protection
against infection following challenge with a heterologous B.
burgdorferi sensu stricto isolate in BALB mice and in some
C3H mice and appeared to limit dissemination in the remain-
ing C3H mice. Spirochetes were recovered only from bladders,
and not from ears or joints, of the partially protected DbpA-
immunized mice, and these spirochetes were highly moribund.
Although C3H mice hyperimmunized with OspAB31 were pro-
tected from dermal challenge with 104 spirochetes of the ho-
mologous B31 isolate, OspA immunity can be overcome by
challenge doses greater than 105 (23) (data not shown). The
spirochetes recovered from OspA-immunized mice in the
study by Fikrig et al. (23) were shown to be ospA escape
mutants and remained viable and infectious, unlike the spiro-
chetes recovered from DbpA-immunized mice. Future exper-
iments will evaluate the disease status of DbpA-immunized
mice harboring reduced numbers of spirochetes at 2 weeks
postchallenge and will determine whether they eventually elim-
inate their infections. It is not known at this time whether the
mice partially protected from infection also had reduced se-
verity of disease or duration of symptoms.
Passive immunization with rabbit antiserum against
DbpA297 appeared to elicit more-complete and broader pro-
tection of C3H mice than active immunization. This response
included protection against isolate N40 expressing DbpA hav-
ing only 67% amino acid sequence identity (75% similarity)
with the DbpA297 immunogen (44). Additionally, we found
that two passive immunizations of as little as 4 ml of the rabbit
pre-DbpA297 antiserum completely protected C3H mice from
challenge with 104 B. burgdorferi B31 spirochetes (Table 3), but
two passive immunizations of the equivalent of 4 ml of BALB
or C3H mouse pre-DbpA297 antiserum (with even higher
DbpA IgG ELISA titers) did not protect naive mice from a
similar challenge (data not shown). Differences in the poten-
cies of the various sera may be due to differences in the re-
sponses of mice, which demonstrate a persistent B. burgdorferi
infection (5, 8), and rabbits, which can clear a B. burgdorferi
infection (25), to protective versus nonprotective epitopes or
the relative avidities of the antibodies contained in the sera.
We do not yet know how broad heterologous protection by
DbpA antibodies may be in nonmurine species, but our in vitro
results summarized in Table 1 provide encouragement.
By immunoblotting, and by blotting with tagged decorin,
isolates HB19, CA-3-87, and 25015 were found to express little
or no DbpA in vitro (Table 1), indicating that these borreliae
had few DbpA targets at the time of challenge. Interestingly,
sera from naive mice infected with HB19 or CA-3-87 reacted
with purified Lpp1:DbpA297 by immunoblotting (data not
shown), suggesting that expression of dbpA by these isolates
was up-regulated in vivo after infection began, possibly at the
time when the passively administered DbpA297 antiserum had
diminished to levels below which protection may have other-
wise been provided.
The high levels of antibodies to DbpB elicited during per-
sistent infection of C3H mice suggested that, like DbpA, DbpB
is also expressed in vivo (Fig. 4). However, the results of pro-
tection and in vitro growth inhibition studies suggest that
DbpB is less vulnerable to antibodies or is expressed at lower
levels than DbpA in vivo, or both. The DbpB sequences of the
isolates examined in this study share .98% identity with
DbpB297 (44), suggesting that serologic variation is not an
explanation for their lack of sensitivity to DbpB297 antibodies.
As we observed that rabbit anti-His-DbpB297 was able to pro-
tect mice partially against a challenge with 104 borreliae, it
appears that accessibility of DbpB to antibodies may differ in
vivo and in vitro. In this regard, others have shown that anti-
bodies from OspC-immunized mice that were protected
against infection had very weak in vitro growth-inhibitory ac-
tivity against the same borrelial isolate used for challenge (41,
42). These preliminary experiments suggested that DbpB is a
less effective target for protection than DbpA, but additional
studies are required to confirm this possibility.
Like the initial reports showing protective immunity target-
ing OspA (19, 48) and OspC (40), we have utilized cultured B.
burgdorferi to demonstrate the protective effect of anti-DbpA
immunity. We have also shown that cross-protection among
heterologous DbpAs is feasible. The next and most critical step
in the evaluation of DbpA vaccines will be to assess whether
DbpA immunity will also confer protection against the tick-
borne route of infection as was eventually shown for OspA and
OspC (24, 27). The protective effects of an anti-DbpA immune
response may extend beyond the transmission-blocking effect
of an OspA immune response, which is apparently effective
only against the spirochete’s arthropod stage in the tick mid-
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gut. If so, immune responses against DbpA may surpass the
efficacy of those elicited by OspA-based vaccines by acting in
concert with immune effector functions in vivo. Furthermore,
mixtures of DbpA and OspA may be synergistic for efficacy. A
multistage, multiantigen strategy is under consideration for
vaccines against Plasmodium falciparum malaria, another ar-
thropod-borne pathogen with developmental regulation of an-
tigen expression (31, 56). This strategy may also be effective for
protection against both infection and disease caused by B.
burgdorferi.
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